Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 8,550,000 shares, a decrease of 5.8% from the August 31st total of 9,080,000 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is currently 5.6 days.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on GOSS. Oppenheimer started coverage on shares of Gossamer Bio in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $9.00 price target for the company. Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Tuesday, August 13th. The Goldman Sachs Group reissued a “buy” rating and issued a $8.00 price objective on shares of Gossamer Bio in a report on Monday, June 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a report on Tuesday, September 17th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $9.20.
Get Our Latest Research Report on GOSS
Institutional Inflows and Outflows
Gossamer Bio Stock Performance
Shares of NASDAQ GOSS traded up $0.03 during midday trading on Monday, hitting $0.99. The company’s stock had a trading volume of 149,034 shares, compared to its average volume of 1,535,027. The company has a debt-to-equity ratio of 2.42, a quick ratio of 8.21 and a current ratio of 8.21. Gossamer Bio has a 1-year low of $0.45 and a 1-year high of $1.60. The firm’s fifty day moving average price is $0.92 and its 200-day moving average price is $0.89. The firm has a market cap of $224.50 million, a P/E ratio of -0.91 and a beta of 1.95.
Gossamer Bio (NASDAQ:GOSS – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $95.84 million during the quarter, compared to the consensus estimate of $160.00 million. On average, sell-side analysts forecast that Gossamer Bio will post -0.33 EPS for the current fiscal year.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Featured Articles
- Five stocks we like better than Gossamer Bio
- How to Use Stock Screeners to Find Stocks
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Overbought Stocks Explained: Should You Trade Them?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Business Services Stocks Investing
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.